Search research articles
Contact Us
Filters
Showing results (81-90 of 183) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study
Rani E George, Wendy B London, Susan L Cohn, et al.
Cancer Letters
|
July 19, 2005
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives
Wendy B London, Luca Boni, Thorsten Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2011
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study
Julie R Park, Jeffrey R Scott, Clinton F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study
Wendy B London, Christopher N Frantz, Laura A Campbell, et al.
Oncogene
|
January 23, 2004
MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma
Chitra F Manohar, James A Bray, Helen R Salwen, et al.
Cancer Research Communications
|
August 5, 2024
Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
Maria E Kaufman, Omar R Vayani, Kelley Moore, et al.
Cancer Research
|
December 25, 2002
SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis
Alexandre Chlenski, Shuqing Liu, Susan E Crawford, et al.
Cancer Research
|
March 3, 2006
The MYCN enigma: significance of MYCN expression in neuroblastoma
Xao X Tang, Huaqing Zhao, Bing Kung, et al.
Pediatric Blood & Cancer
|
September 17, 2013
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project
Yaël P Mossé, Rebecca J Deyell, Frank Berthold, et al.
Pediatric Blood & Cancer
|
September 23, 2010
The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth
Nisha C Kakodkar, Radhika Peddinti, Morris Kletzel, et al.
Page
of 19
Search research articles
Search
Showing results (81-90 of 183) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study
Rani E George, Wendy B London, Susan L Cohn, et al.
Cancer Letters
|
July 19, 2005
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives
Wendy B London, Luca Boni, Thorsten Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2011
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study
Julie R Park, Jeffrey R Scott, Clinton F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study
Wendy B London, Christopher N Frantz, Laura A Campbell, et al.
Oncogene
|
January 23, 2004
MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma
Chitra F Manohar, James A Bray, Helen R Salwen, et al.
Cancer Research Communications
|
August 5, 2024
Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures
Maria E Kaufman, Omar R Vayani, Kelley Moore, et al.
Cancer Research
|
December 25, 2002
SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis
Alexandre Chlenski, Shuqing Liu, Susan E Crawford, et al.
Cancer Research
|
March 3, 2006
The MYCN enigma: significance of MYCN expression in neuroblastoma
Xao X Tang, Huaqing Zhao, Bing Kung, et al.
Pediatric Blood & Cancer
|
September 17, 2013
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project
Yaël P Mossé, Rebecca J Deyell, Frank Berthold, et al.
Pediatric Blood & Cancer
|
September 23, 2010
The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth
Nisha C Kakodkar, Radhika Peddinti, Morris Kletzel, et al.
Page
of 19